Clinical Trials
37 trialsStudy to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
A Rollover Study of CC-122
Bristol-Myers Squibb
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Janssen Research & Development, LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
AbbVie
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
National Institutes of Health Clinical Center (CC)
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
Ascentage Pharma Group Inc.
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
City of Hope Medical Center
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta, Inc.
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
BeOne Medicines
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
National Institutes of Health Clinical Center (CC)
CRETI-NH
Baylor College of Medicine
453 Ph1 CLL
AbbVie
Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
SAVE
Dana-Farber Cancer Institute
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
City of Hope Medical Center
huCART19-IL18 in CD19+ Cancers
University of Pennsylvania
Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients
University of California, San Diego
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
City of Hope Medical Center
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
City of Hope Medical Center
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Sana Biotechnology
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
University of Alabama at Birmingham
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Jonsson Comprehensive Cancer Center
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
Memorial Sloan Kettering Cancer Center
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
Acerta Pharma BV
MULTIPRAT
Baylor College of Medicine
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
Case Comprehensive Cancer Center
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Bio-Path Holdings, Inc.
A Study of FCN-338 in Patients With Chronic CLL/SLL
Fochon Pharmaceuticals, Ltd.
ZGR in TN CLL
Institute of Hematology & Blood Diseases Hospital, China
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
University of California, San Diego